ONCAlert | 2017 San Antonio Breast Cancer Symposium

Impact of CheckMate-238 Results for Patients With Melanoma

Jeffrey S. Weber, MD, PhD
Published Online:11:31 AM, Mon September 18, 2017

Jeffrey S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses how results of the CheckMate-238 study will impact patients with melanoma.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.